Literature DB >> 17641898

Successful treatment with rituximab in a patient with mental nerve neuropathy in primary Sjögren's syndrome.

Pascal Sève1, Emilie Gachon, Philippe Petiot, Katia Stankovic, Annick Charhon, Christiane Broussolle.   

Abstract

We present the case of a 79-year-old female patient with chronic obstructive pulmonary disease on home oxygen therapy who was diagnosed as having Sjögren's syndrome with arthralgias and painful sensory neuropathy. She subsequently developed bilateral numb chin syndrome. Because of refractory and disabling symptoms under high corticosteroids and severe chronic obstructive pulmonary disease, we decided to treat her with rituximab rather than immunosuppressants. This resulted in significant subjective improvement in sicca syndrome while arthalgias, distal and chin paresthesias resolved completely. To our knowledge this is the first description of such a case.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17641898     DOI: 10.1007/s00296-007-0396-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  12 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  The numb chin syndrome: a critical sign for primary care physicians.

Authors:  Jon M Sweet
Journal:  Arch Intern Med       Date:  2004-06-28

3.  Successful treatment of a patient with primary Sjögren's syndrome with Rituximab.

Authors:  Troels Ring; Maria Kallenbach; Jeppe Praetorius; Søren Nielsen; Birgitte Melgaard
Journal:  Clin Rheumatol       Date:  2005-11-08       Impact factor: 2.980

4.  Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab.

Authors:  K Ahmadi-Simab; P Lamprecht; B Nölle; M Ai; W L Gross
Journal:  Ann Rheum Dis       Date:  2005-07       Impact factor: 19.103

5.  The wide spectrum of clinical manifestations in Sjögren's syndrome-associated neuropathy.

Authors:  Keiko Mori; Masahiro Iijima; Haruki Koike; Naoki Hattori; Fumiaki Tanaka; Hirohisa Watanabe; Masahisa Katsuno; Asako Fujita; Ikuko Aiba; Akihiko Ogata; Toyokazu Saito; Kunihiko Asakura; Mari Yoshida; Masaaki Hirayama; Gen Sobue
Journal:  Brain       Date:  2005-07-27       Impact factor: 13.501

6.  Trigeminal neuropathy in connective tissue disease.

Authors:  B Ashworth; G B Tait
Journal:  Neurology       Date:  1971-06       Impact factor: 9.910

7.  Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.

Authors:  J Pijpe; G W van Imhoff; F K L Spijkervet; J L N Roodenburg; G J Wolbink; K Mansour; A Vissink; C G M Kallenberg; H Bootsma
Journal:  Arthritis Rheum       Date:  2005-09

8.  Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.

Authors:  Raphaèle Seror; Christelle Sordet; Loic Guillevin; Eric Hachulla; Charles Masson; Marc Ittah; Sophie Candon; Véronique Le Guern; Achille Aouba; Jean Sibilia; Jacques-Eric Gottenberg; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2006-09-01       Impact factor: 19.103

Review 9.  B cell targeted therapies in autoimmune diseases.

Authors:  David A Isenberg
Journal:  J Rheumatol Suppl       Date:  2006-05

10.  Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients.

Authors:  Sophie Delalande; Jérôme de Seze; Anne-Laure Fauchais; Eric Hachulla; Tanya Stojkovic; Didier Ferriby; Sylvain Dubucquoi; Jean-Pierre Pruvo; Patrick Vermersch; Pierre-Yves Hatron
Journal:  Medicine (Baltimore)       Date:  2004-09       Impact factor: 1.889

View more
  3 in total

1.  Practical considerations on the use of rituximab in autoimmune neurological disorders.

Authors:  Mixalis L Kosmidis; Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

Review 2.  Cellular targeting in autoimmunity.

Authors:  Jennifer L Rogers; Donald S Serafin; Roman G Timoshchenko; Teresa K Tarrant
Journal:  Curr Allergy Asthma Rep       Date:  2012-12       Impact factor: 4.806

3.  Neuro-Sjögren: Uncommon or underestimated problem?

Authors:  Marta Jaskólska; Magdalena Chylińska; Anna Masiak; Mariusz Siemiński; Marcin Ziętkiewicz; Zenobia Czuszyńska; Żaneta Smoleńska; Zbigniew Zdrojewski
Journal:  Brain Behav       Date:  2020-06-25       Impact factor: 2.708

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.